Outcomes Of Homograft Pulmonary Valve Replacement At Viet Duc University Hospital

Abstract

Abstract: Introduction: Pulmonary valve disease is the least common of valvular heart diseases and is primarily associated with congenital heart diseases such as pulmonary valve stenosis, pulmonary valve atresia with ventricular septal defect, tetralogy of Fallot, double-outlet right ventricle with pulmonary valve stenosis, or pulmonary regurgitation after total repair of congenital heart disease. Pulmonary valve replacement remains the mainstay of treatment for pulmonary valve disease. The purpose of the study was to evaluate the outcomes of homograft pulmonary valve replacement at Viet Duc University Hospital. Methods: A retrospective cross-sectional study was conducted on patients who underwent pulmonary valve replacement with cryopreserved homograft valve at the Cardiovascular and Thoracic Center, Viet Duc University Hospital, from January 2019 to December 2024. Results: The study included 30 patients, of whom 63.3% were male, with a mean age of 26.5 ± 11.7 years (14 - 56). The most common lesion was pulmonary regurgitation after total repair of congenital heart disease (60%). Mean cardiopulmonary bypass time was 101.6 ± 48.1 minutes (45 - 252), and mean operative time was 262.9 ± 73.9 minutes (107 - 457). The most frequent postoperative complication was prolonged mechanical ventilation (13.3%), and early mortality was 0%. Postoperatively, 93.3% of patients showed improvement in clinical symptoms, and 73.3% of pulmonary valve replacement operations were graded as good. Mean follow-up duration was 35 months (2 - 63), survival was 100% at 5 years, freedom from reoperation was 96.7% at 5 years, and freedom from homograft failure was 96.7% at 5 years. Conclusion: This study demonstrated that homograft pulmonary valve replacement at Viet Duc University Hospital is safe, has low complication rates and provides good early and mid-term outcomes.